The total transaction value could exceed $568 million.
News
Teva undergoes rebranding
The “refreshed visual identity” includes a new digital platform entitled ‘Life Effects’.
Women ‘risking’ lives, not doing bowel screening tests
While 81% of women take part in cervical cancer screening and 73% in breast cancer screening, only 60% of women take part in bowel screening.
UK in ‘desperate’ need of thousands more GPs
The number of fully qualified, full-time equivalent GPs fell by 576 in the year from June 2018 to June 2019.
ABPI launches NHS, industry partnership guideline
Joint projects include identification of undiagnosed patients, improving patient adherence to medicines and contributions to nurse services.
NICE nod for Novartis’ Luxturna
The treatment has been approved for RPE65-mediated inherited retinal dystrophies.
Greater Manchester NHS declares climate emergency
Organisations are already making progress in reducing carbon emissions and tackling environment degradation.
Gyroscope Theraputics secures £50.4m Series B financing
Syncona and Cambridge Innovation Capital will contribute £48 million and £2.4 million, respectively.
NHS warns parents as ‘asthma season’ hits
At this time of year cases can more than double.
NICE publishes draft cerebral palsy quality standard
The draft standard consists of five statements, which together highlight what needs to be done to ensure adults with cerebral palsy can be “as independent as possible and have equal access to every available opportunity.”
IBD research smashes recruitment target two years early
In the UK, at least 300,000 people are affected by Crohn’s disease or ulcerative colitis.
Novartis announces positive results from two Entresto trials
Heart failure is a chronic and progressive condition, which impacts 26 million people worldwide.
C4X forms Drug Discovery Advisory Network
The team will act as ambassadors for C4XD within the Biotech and Pharmaceutical community.
Xofluza effective as preventative flu medicine
Xofluza is the first and only one-dose oral medicine approved to treat flu in otherwise healthy patients.
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
